Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. Lachowiez CA, Zeidner JF, Othman J, Kaempf A, et al. J Clin Oncol 2026;44:2422-2434.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lachowiez CA, Zeidner JF, Othman J, Kaempf A, et al. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. J Clin Oncol 2026;44:2422-2434.
PMID: 42391582